Source: The Korea Times, by Park Yoon-bae (September 27, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- Sungkyunkwan University’s organoid-on-a-chip monitored Parkinson’s brainstem organoids for 12 hours using a microfluidic chip.
- Gold nanoholes, an optical resonator, and a dopamine-responsive aptamer detected dopamine release without damaging tissue.
- The findings identify an optimal dosage in an organoid model, but do not establish clinical effectiveness in patients.
Researchers at Sungkyunkwan University have built an organoid-on-a-chip platform that tracked Parkinson’s disease treatment responses in living brainstem-like tissue for 12 hours. The system pairs stem cell-derived brain organoids, often called mini-brains, with a highly sensitive optical sensor that detects dopamine without damaging the tissue. Led by professors Kim In-ki and Park Jong-chan, the work offers a way to observe not only whether a drug works, but also when its effect begins, peaks, and fades. That timing could make laboratory drug testing more informative before treatments move toward human clinical trials.
A living model of Parkinson’s disease
An organoid is a three-dimensional cluster of cells grown from human stem cells that reproduces selected features of an organ. Here, the researchers created organoids that mimic the brainstem, the region connecting the brain and spinal cord that helps regulate movement, breathing, and other essential functions.
Parkinson’s disease involves damage to dopamine-producing neurons. Dopamine is a chemical messenger that helps control movement, and its loss contributes to symptoms including tremors and muscle stiffness. A model that releases dopamine can therefore give researchers a useful readout of how a potential treatment affects disease-related biology.
Using light to measure dopamine
Conventional experiments often require researchers to destroy cells or apply special stains to measure a drug response. Those methods can capture a single snapshot, but they make it difficult to watch the same living tissue over time. The Sungkyunkwan University platform was designed to avoid that tradeoff.
The sensor uses an aptamer, a short artificial DNA molecule engineered to respond to dopamine. It sits on a surface containing gold nanoholes and a vertical optical resonator. Like a singer whose voice becomes louder in a carefully shaped room, light can become especially responsive when it interacts with these precisely arranged gold structures. Changes associated with dopamine release alter that optical signal.
This nanoplasmonic approach detects dopamine with high sensitivity while leaving the organoids intact. The researchers could therefore follow chemical changes in living tissue instead of repeatedly sacrificing samples for separate measurements.
Tiny channels deliver drugs and nutrients
The biological model and optical sensor were integrated with a microfluidic chip, a device containing tiny channels that guide fluids with precision. The chip delivered culture media and drugs to the Parkinson’s disease brainstem organoids while the sensor monitored dopamine release in real time.
During a 12-hour experiment, the team tracked the organoids’ responses to treatment. The measurements showed that raising a drug’s concentration did not automatically produce a stronger therapeutic effect. The researchers identified an optimal dosage that produced the most favorable response in their model.
That result illustrates why continuous measurement matters. A drug test is not just a question of whether dopamine changes. It also involves the timing of the response, the maximum effect reached, and how long that effect persists.
Why This Matters
Drug development frequently depends on animal studies and simplified cell experiments before a candidate reaches human testing. Brain organoids cannot replace clinical trials, but they can provide a human tissue-based model that may help researchers study responses that animal models cannot fully capture.
Professor Kim said the work opens a path to continuously monitoring drug responses in living human tissue with an ultra-precise optical sensor. The team plans to develop the platform for patient-specific drug development and disease treatment, potentially using organoids made from an individual patient’s cells to compare treatment responses.
The study, published in ACS Nano, was conducted by teams led by Kim and Park in Sungkyunkwan University’s Department of Biophysics. Ph.D. candidates Cho Han-jun and Kim Young-jun and master’s candidate Yoon Na-hyun were first authors. Next, the platform will need to show how broadly its measurements translate across drugs, organoid models, and patient-specific samples.
Topics: Biosensors · Brain & neurological health · Drug development & safety
Start here: Biosensors explained